We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Beckman Coulter Life Sciences Acquires Blue Ocean Biomedical

By LabMedica International staff writers
Posted on 18 Apr 2012
Print article
Beckman Coulter Life Sciences (Indianapolis, IN, USA) has acquired Blue Ocean Biomedical, LLC (Pembroke Pines, FL, USA), manufacturer of automated flow cytometry systems and reagents. The transaction provides Beckman Coulter Life Sciences with low complexity analyzers that integrate automated sample preparation and directly address emerging flow cytometry-market trends.

Driving growth through internal product development and through acquisition of differentiated businesses and technologies is a core strategy for Beckman Coulter Life Sciences. The transaction expands the company’s flow cytometry line and targets routine clinical analyses. Blue Ocean Biomedical products complement the company’s existing cytometry portfolio with instruments based on a “sample in, result out” (SIRO) approach that represents a fundamental change in the routine clinical analysis sector.

“This acquisition provides both immediate opportunity and long-term value,” said Scott Atkin, president, Beckman Coulter Life Sciences. “The simplification of customer workflows will be dramatic. We’ll be able to offer customers an extended line of market leading technology while expanding our reach within a key segment for flow cytometry.”

Blue Ocean Biomedical products provide the first true integration of sample preparation, handling, analysis and data management, and the only SIRO solution for clinical flow cytometry, and will enable Beckman Coulter Life Sciences to deliver an expanding portfolio of clinical testing to a broader global market.

“Our team has developed a line of truly unique instrument systems: essentially, the world’s first ‘load & go’ flow cytometers,” said Mike Brochu, CEO and cofounder of Blue Ocean Biomedical. “With its history of leadership and innovation in this field, Beckman Coulter has all the resources and technology needed to build on this platform and future systems for years to come.”

Related Links:
Beckman Coulter
Blue Ocean Biomedical



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: The new blood test identifies key biomarkers of osteoarthritis (Photo courtesy of Shutterstock)

Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays

Osteoarthritis (OA) is the most prevalent form of arthritis, impacting millions worldwide and resulting in significant economic and social costs. Although no cure exists currently, the effectiveness of... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: The Sampler device could revolutionize sample collection for diagnostic tests (Photo courtesy of ReadyGo Diagnostics)

First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests

The COVID pandemic has dramatically reshaped the perception of diagnostics. Post the pandemic, a groundbreaking device that combines sample collection and processing into a single, easy-to-use disposable... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.